Phibro Animal Health Corporation (PAHC)
Return on equity (ROE)
Jun 30, 2024 | Jun 30, 2023 | Jun 30, 2022 | Jun 30, 2021 | Jun 30, 2020 | ||
---|---|---|---|---|---|---|
Net income | US$ in thousands | 2,416 | 32,606 | 49,175 | 54,385 | 33,552 |
Total stockholders’ equity | US$ in thousands | 256,641 | 282,509 | 262,442 | 238,529 | 188,204 |
ROE | 0.94% | 11.54% | 18.74% | 22.80% | 17.83% |
June 30, 2024 calculation
ROE = Net income ÷ Total stockholders’ equity
= $2,416K ÷ $256,641K
= 0.94%
Phibro Animal Health Corporation's return on equity (ROE) has shown a declining trend over the past five years, decreasing from 17.83% in 2020 to 0.94% in 2024. This decrease indicates a deteriorating performance in generating profits relative to shareholders' equity. The ROE of 0.94% in 2024 raises concerns about the company's ability to effectively use equity to generate returns for shareholders. Further analysis would be required to understand the reasons behind this decline and to assess the company's overall financial health and efficiency in utilizing shareholder funds.
Peer comparison
Jun 30, 2024
Company name
Symbol
ROE
Phibro Animal Health Corporation
PAHC
0.94%
Abbott Laboratories
ABT
14.83%
AbbVie Inc
ABBV
46.94%
Alkermes Plc
ALKS
29.58%
Amphastar P
AMPH
21.51%
ANI Pharmaceuticals Inc
ANIP
4.34%
Arcus Biosciences Inc
RCUS
-66.45%
Biomarin Pharmaceutical Inc
BMRN
3.39%
Bristol-Myers Squibb Company
BMY
27.27%
Catalent Inc
CTLT
-28.94%
Catalyst Pharmaceuticals Inc
CPRX
18.41%